Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
Elizabeth H StoverCoyin OhPaula KeskulaAtish D ChoudhuryYuen-Yi TsengViktor A AdalsteinssonJens G LohrAaron R ThornerMatthew DucarGregory V KryukovGavin HaMara RosenbergSamuel S FreemanZhenwei ZhangXiaoyun WuEliezer M Van AllenDavid Y TakedaMassimo LodaChin-Lee WuMary-Ellen TaplinLevi A GarrawayJesse S BoehmFranklin W HuangPublished in: The Prostate (2022)
We evaluated a prostate cancer-specific targeted NGS panel to detect common and clinically relevant alterations (including ETS family gene fusions) in prostate cancer. The panel detected driver mutations in a diverse set of clinical samples of prostate cancer, including fresh-frozen tumors, cell-free DNA, CTCs, and cell lines. Targeted sequencing of patient-derived cell lines highlights the challenge of deriving cell lines from primary prostate cancers and the importance of genomic characterization to credential candidate cell lines. Our study supports that a prostate cancer-specific targeted sequencing panel provides an efficient, clinically feasible approach to identify genetic alterations across a spectrum of prostate cancer samples and cell lines.